Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells

References

• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23:suppl 12 40 - 7; PMID: 8941409
   PubMed Web of Science ®Google Scholar
• Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, et al. Docetaxel-carboplatin as first line che motherapy for epithelial ovarian cancer. Br J Cancer 2001; 84:170 - 8; http://dx.doi.org/10.1054/bjoc.2000.1572; PMID: 11161372
   PubMed Web of Science ®Google Scholar
• Ducton CJ. New options for the treatment of advanced ovarian cancer. Semin Oncol 1997; 24:Suppl 5 2 - 11
   Google Scholar
• Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20:1238 - 47; http://dx.doi.org/10.1200/JCO.20.5.1238; PMID: 11870166
   PubMed Web of Science ®Google Scholar
• Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 2006; 6:333 - 63; http://dx.doi.org/10.2174/156800906777441799; PMID: 16848724
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271 - 5; http://dx.doi.org/10.1038/20459; PMID: 10353251
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408 - 16; PMID: 9537241
   PubMed Web of Science ®Google Scholar
• Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007; 38:1310 - 20; http://dx.doi.org/10.1016/j.humpath.2007.02.010; PMID: 17555795
   PubMed Web of Science ®Google Scholar
• Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7:1661 - 8; PMID: 11410504
   PubMed Web of Science ®Google Scholar
• Olson MF. Application for ROCK kinase inhibition. Curr Opin Cell Biol 2008; 20:242 - 8; http://dx.doi.org/10.1016/j.ceb.2008.01.002; PMID: 18282695
   PubMed Web of Science ®Google Scholar
• Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, et al. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008; 7:1551 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-07-0428; PMID: 18566226
   PubMed Web of Science ®Google Scholar
• Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behavior. Nat Rev Mol Cell Biol 2003; 4:446 - 56; http://dx.doi.org/10.1038/nrm1128; PMID: 12778124
   PubMed Web of Science ®Google Scholar
• Scott RW, Olson MF. LIM kinase: function, regulation and association with human disease. J Mol Med 2007; 85:555 - 68; http://dx.doi.org/10.1007/s00109-007-0165-6; PMID: 17294230
   PubMed Web of Science ®Google Scholar
• Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325 - 58; PMID: 14506307
   PubMed Web of Science ®Google Scholar
• Zicha D, Dobbie IM, Holy MR, Monypenny J, Soong DY, Gray C, et al. Rapid actin transport during cell protrusion. Science 2003; 300:142 - 5; http://dx.doi.org/10.1126/science.1082026; PMID: 12677069
   PubMed Web of Science ®Google Scholar
• Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000; 261:44 - 51; http://dx.doi.org/10.1006/excr.2000.5046; PMID: 11082274
   PubMed Web of Science ®Google Scholar
• Redowicz MJ. Rho-associated kinase: involvement in the cytoskeleton regulation. Arch Biochem Biophys 1999; 364:122 - 4; http://dx.doi.org/10.1006/abbi.1999.1112; PMID: 10087173
   PubMed Web of Science ®Google Scholar
• Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E, et al. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008; 38:810 - 7; http://dx.doi.org/10.1111/j.1872-034X.2008.00333.x; PMID: 18507693
   PubMed Web of Science ®Google Scholar
• Sawada K, Morishige K, Tahara M, Ikebuchi Y, Kawagishi R, Tasaka K, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol 2002; 87:252 - 9; http://dx.doi.org/10.1006/gyno.2002.6831; PMID: 12468322
   PubMed Web of Science ®Google Scholar
• Ying H, Sandara LB, Li WW, Alicke B, Xuan JA, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5:2158 - 64; http://dx.doi.org/10.1158/1535-7163.MCT-05-0440; PMID: 16985048
   PubMed Web of Science ®Google Scholar
• Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, Suzuki Y, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1999; 141:13 - 9; http://dx.doi.org/10.1007/s007010050260; PMID: 10071681
   PubMed Web of Science ®Google Scholar
• Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238:31 - 9; http://dx.doi.org/10.1016/j.jns.2005.06.003; PMID: 16005902
   PubMed Web of Science ®Google Scholar
• Igishi T, Mikami M, Murakami K, Matsumoto S, Shigeoka Y, Nakanishi H, et al. Enhancement of cisplatin-induced cytotoxicity by ROCK inhibitor through suppression of focal adhesion kinase-independent mechanism in lung carcinoma cells. Int J Oncol 2003; 23:1079 - 85; PMID: 12963988
   PubMed Web of Science ®Google Scholar
• Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and –sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34:2583 - 6; http://dx.doi.org/10.1016/0006-2952(85)90551-9; PMID: 4040369
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in invitro and in vivo ovarian cancer models. J Biol Chem 2004; 279:23477 - 85; http://dx.doi.org/10.1074/jbc.M313709200; PMID: 15026414
   PubMed Web of Science ®Google Scholar
• Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007; 6:1517 - 25; http://dx.doi.org/10.1158/1535-7163.MCT-06-0689; PMID: 17513600
   PubMed Web of Science ®Google Scholar
• Kothakota S, Azuma T, Reinhard C, Kippel A, Tang J, Chu K, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278:294 - 8; http://dx.doi.org/10.1126/science.278.5336.294; PMID: 9323209
   PubMed Web of Science ®Google Scholar
• Duyndam MC, Berkel MPA, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74:191 - 201; http://dx.doi.org/10.1016/j.bcp.2007.04.003; PMID: 17498666
   PubMed Web of Science ®Google Scholar
• Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, et al. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 2007; 26:2262 - 73; http://dx.doi.org/10.1038/sj.emboj.7601683; PMID: 17446864
   PubMed Web of Science ®Google Scholar
• Shibata R, Kai H, Seki Y, Kusaba K, Takemiya K, Koga M, et al. Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis. J Cardiovasc Pharmacol 2003; 42:Suppl 1 S43 - 7; http://dx.doi.org/10.1097/00005344-200312001-00011; PMID: 14871028
   PubMedGoogle Scholar
• Moore M, Marroquin BA, Gugliotta W, Tse R, White SR. Rho kinase inhibition initiates apoptosis in human airway epithelial cells. Am J Respir Cell Mol Biol 2004; 30:379 - 87; http://dx.doi.org/10.1165/rcmb.2003-0019OC; PMID: 12933355
   PubMed Web of Science ®Google Scholar
• Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis. [review] Int J Mol Med 2000; 5:253 - 9; PMID: 10677565
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallance TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible Factor-1-dependent regulation of multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387 - 94; PMID: 12067980
   PubMed Web of Science ®Google Scholar
• Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277:38205 - 11; http://dx.doi.org/10.1074/jbc.M203781200; PMID: 12149254
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009; 15:492 - 501; http://dx.doi.org/10.1158/1078-0432.CCR-08-1945; PMID: 19147754
   PubMed Web of Science ®Google Scholar